| Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
|---|---|---|---|---|---|
Gross Sales | 5,646 | 5,386 | 5,176 | 4,911 | 4,553 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,646 | 5,386 | 5,176 | 4,911 | 4,553 |
Other Operating Income | 102 | 91 | 75 | 71 | 85 |
Other Income | 8 | 86 | 60 | -1 | 46 |
Total Income | 5,756 | 5,563 | 5,311 | 4,981 | 4,684 |
Total Expenditure | 3,905 | 3,725 | 3,635 | 3,531 | 3,247 |
PBIDT | 1,851 | 1,838 | 1,676 | 1,450 | 1,437 |
Interest | 139 | 160 | 194 | 209 | 124 |
PBDT | 1,712 | 1,678 | 1,482 | 1,241 | 1,313 |
Depreciation | 395 | 416 | 392 | 389 | 318 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 282 | 248 | 214 | 189 | 185 |
Deferred Tax | 125 | 122 | 112 | 84 | 144 |
Reported Profit After Tax | 910 | 892 | 764 | 579 | 666 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 910 | 892 | 764 | 579 | 666 |
Extra-ordinary Items | 0 | 88 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 910 | 804 | 764 | 579 | 666 |
EPS (Unit Curr.) | 26.88 | 26.35 | 22.57 | 17.11 | 19.67 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 169.23 | 169.23 | 169.23 | 169.23 | 169.23 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 32.78 | 34.12 | 32.38 | 29.52 | 31.56 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 16.11 | 16.56 | 14.76 | 11.78 | 14.62 |
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
